Results 161 to 169 of about 1,816 (169)

Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV‐Infected Subjects

Clinical Pharmacology in Drug Development, 2019
Mayu Osawa, Takayo Ueno, Hanbin Li
exaly  

Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction

Journal of Medical Virology, 2017
Michio Imamura, Yoshiiku Kawakami, Kana Daijo   +2 more
exaly  

Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir

Clinical Case Reports (discontinued), 2016
Fiona Mcphee
exaly  

Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection

JGH Open, 2017
Taiga Ōtsuka, Yasunori Kawaguchi, Toshihiko Mizuta   +2 more
exaly  

Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects

Journal of Clinical Pharmacology, 2019
Mayu Osawa, Takayo Ueno, Hanbin Li
exaly  

Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease

Hepatology Research, 2017
Chisa Kondo, Masanori Atsukawa, Akihito Tsubota   +2 more
exaly  

Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study

Journal of Viral Hepatitis, 2016
Hideki Ohdan, K Chayama
exaly  

Asunaprevir/daclatasvir/tacrolimus

Reactions Weekly, 2016
openaire   +1 more source

Asunaprevir/beclabuvir/daclatasvir

Reactions Weekly, 2018
openaire   +1 more source